Different impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patients | Zendy

Sergio SerranoVillar | Zendy; Yan Zhou | Zendy; Anthony Rodgers | Zendy; Santiago Moreno | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Different impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patients

Author(s) -

Sergio SerranoVillar,

Yan Zhou,

Anthony Rodgers,

Santiago Moreno

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw375

Subject(s) - raltegravir , efavirenz , hazard ratio , cd4 cd8 ratio , medicine , integrase inhibitor , proportional hazards model , pharmacology , cd8 , confidence interval , human immunodeficiency virus (hiv) , immunology , viral load , lymphocyte subsets , antiretroviral therapy , immune system

A low CD4/CD8 ratio during treated HIV identifies individuals with heightened immunoactivation and excess mortality. Whether ART regimens elicit distinct CD4/CD8 ratio recovery remains unknown. We aimed to compare the efficacy of an integrase inhibitor versus a non-nucleoside to normalize the CD4/CD8 ratio.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research